These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 27501275)

  • 1. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
    Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
    Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
    Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
    Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
    Luque S; Lúcia M; Melilli E; Lefaucheur C; Crespo M; Loupy A; Bernal-Casas D; Gomà M; Jarque M; Crespo E; Montero N; Manonelles A; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
    Am J Transplant; 2019 Feb; 19(2):368-380. PubMed ID: 30085394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung intragraft donor-specific antibodies as a risk factor for graft loss.
    Visentin J; Chartier A; Massara L; Linares G; Guidicelli G; Blanchard E; Parrens M; Begueret H; Dromer C; Taupin JL
    J Heart Lung Transplant; 2016 Dec; 35(12):1418-1426. PubMed ID: 27450460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss.
    Courant M; Visentin J; Linares G; Dubois V; Lepreux S; Guidicelli G; Thaunat O; Merville P; Couzi L; Taupin JL
    Nephrol Dial Transplant; 2018 Oct; 33(10):1853-1863. PubMed ID: 29672702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.
    Senev A; Coemans M; Lerut E; Van Sandt V; Daniëls L; Kuypers D; Sprangers B; Emonds MP; Naesens M
    Am J Transplant; 2019 Mar; 19(3):763-780. PubMed ID: 30107078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort.
    Gautier Vargas G; Olagne J; Parissiadis A; Joly M; Cognard N; Perrin P; Froelich N; Guntz P; Gachet C; Moulin B; Caillard S
    Transplantation; 2020 Oct; 104(10):2148-2157. PubMed ID: 31895344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients.
    Cioni M; Nocera A; Innocente A; Tagliamacco A; Trivelli A; Basso S; Quartuccio G; Fontana I; Magnasco A; Drago F; Gurrado A; Guido I; Compagno F; Garibotto G; Klersy C; Verrina E; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
    J Immunol Res; 2017; 2017():1747030. PubMed ID: 28367453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis.
    Kiberd BA; Miller A; Martin S; Tennankore KK
    Am J Transplant; 2016 Nov; 16(11):3212-3219. PubMed ID: 27106124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome.
    Bachelet T; Couzi L; Lepreux S; Legeret M; Pariscoat G; Guidicelli G; Merville P; Taupin JL
    Am J Transplant; 2013 Nov; 13(11):2855-64. PubMed ID: 24102857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients.
    Wehmeier C; Hönger G; Cun H; Amico P; Hirt-Minkowski P; Georgalis A; Hopfer H; Dickenmann M; Steiger J; Schaub S
    Am J Transplant; 2017 Aug; 17(8):2092-2102. PubMed ID: 28245084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of protocol kidney biopsies for de novo donor-specific antibodies.
    Parajuli S; Reville PK; Ellis TM; Djamali A; Mandelbrot DA
    Am J Transplant; 2017 Dec; 17(12):3210-3218. PubMed ID: 28805293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant development of C1q-positive HLA antibodies and kidney graft survival.
    Piazza A; Poggi E; Ozzella G; Adorno D
    Clin Transpl; 2013; ():367-75. PubMed ID: 25095531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
    Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
    Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.